vcrs removal from asx 300 and the asx sp ind, page-6

I have to agree, although i'm biased cause i hold.
But yes the Ventrasist will be in a few years the best product of choice available on the market.
The question is this though, will acceptance of LVAD's be strong enough to support a one product company like VCR.
The medical profession will be the one's who decide that.
As for the share price...we all know it stinks, what more can be said.